Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Italian merger set in drug ingredients
by Michael McCoy
May 30, 2016
| A version of this story appeared in
Volume 94, Issue 22
The Italian firm Olon has acquired its rival Infa in a deal that will create one of Europe’s largest pharmaceutical chemical makers. The combined company expects its sales this year to exceed $335 million. It will operate seven plants in Italy and one in Spain that make active ingredients for generic drugs and provide contract manufacturing. The combined firm is owned by Italy’s P&R Group, which also owns the drug company Fidia Farmaceutici and the resin maker Sir Industriale.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X